Today, a doctor asks a patient to follow my finger, but neuroClues wants clinicians to use its proprietary, portable headsets to instead capture eye movements at 800 frames per second, after which they can run an analysis of the data in just a few seconds.The three-and-half-year-old outfits founders two of whom are neuroscience researchers point to high rates of misdiagnosis of Parkinsons as one of the factors informing their decision to focus on the disease first. The product is geared toward football players and athletes in other contact sports who face elevated risk of head injury.There are also mobile app makers such as BrainEye pitching consumers on smartphone-based eye-tracking tech for self-testing brain health. The outfits founders further argue that by building its own hardware and software, neuroClues enjoys unrivaled speed of data capture in a commercially deployed, non-static device.To protect these ostensible advantages, neuroClues has a number of patents granted (or filed) that it says cover various aspects of the design, such as the synchronization of the hardware and software, and its approach to analyzing data.We are the only one on the market today that is recording 800 frames per second on a portable device, said Pouppez, noting that the research gold standard is 1,000 frames per second. The company says its also talking to a number of other outfits in the U.S. and Europe that are interested in its hardware and software.This first version of the device is designed as a diagnostic aid, meaning a clinician is still responsible for interpreting the results. Existing investors Invest.BW, plus a number of business angels, including Fiona du Monceau, former Chair of the Board at UCB, Artwall, and Olivier Legrain, CEO of IBA, also participated.